Becton, Dickinson & Company is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues.
Industry sector: Medical
Sector classification: Surgical & medical instruments
Deep Learning based analysis and prediction model for Becton, Dickinson and Company (BDX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 2, 2015.
Market data for BDX model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for BDX.
Model is being retrained on a daily basis.
|% Held by Insiders||1.00%|
|% Held by Institutions||83.70%|
|EPS (last reported FY)||$9.48|
|EPS (last reported Q)||$2.48|
|EPS, estimated (last reported Q)||$2.40|
|Total revenues||$12 B|
|Net income||$1 B|